Table 5.
Indications for FDG PET-CT by paediatric tumour type, and key supporting in-text referenced evidence
| Use of PET-CT | |||||
| Pathology | Biopsy targeting | Staging | Interim | Response assessment | Recurrence |
| Haematological | |||||
| Hodgkin’s | 6, 12–17 | 10–21 | 23 | 20 | |
| Non-Hodgkin’s | 19, 36 | 21, 36 | |||
| Leukaemia | 48 | 48 | 49 | ||
| Sarcoma | |||||
| Osteosarcoma | 52–54 | 59–61 | 58, 60, 65–67 | 61, 68 | |
| Ewing’s sarcoma | 54, 71 | 72, 73 | 64, 66 | ||
| Rhabdmyosarcoma | 75–81 | 82 | 83 | ||
| MPNST | 89 | 87, 88 | |||
| CNS tumours | 38–40, 42, 43 | ||||
| Neuroblastoma | 90, 91, 93 | 94 | |||
FDG, fluorodeoxyglucose ; PET, positron emission tomography.